Study Of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, Or Colorectal Cancer.

Study Overview

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

OBJECTIVES: Primary * To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups. Secondary * To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy. OUTLINE: This is a multicenter study. Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Breast Cancer
Colorectal Cancer
Lung Cancer
Melanoma (Skin)
Pancreatic Cancer

CTRIAL-IE (ICORG) 07-12
EU-20949

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2009-09-09	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2017-05-23
First Submitted that Met QC Criteria 2009-09-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2017-05-24
First Posted (ACTUAL) 2009-09-10	Results First Posted N/A	Last Verified 2017-05

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Breast
: Lung
: Melanoma
: Pancreatic
: Colorectal

Primary Outcome Measures	Measure Description	Time Frame
Detection of peptide and protein markers in serum		Ongoing

Secondary Outcome Measures	Measure Description	Time Frame
Identification of the protein/peptide involved		Ongoing

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

Diagnosis of 1 of the following advanced metastatic malignancies:

Malignant melanoma
Lung cancer
Breast cancer
Pancreatic carcinoma
Colorectal cancer
Advanced and/or metastatic disease
Hormone receptor status not specified

Menopausal status not specified

Not specified

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Martin Clynes, National Institute for Cellular Biotechnology at Dublin City University

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record